英夫利西单抗治疗类风湿关节炎的临床疗效观察  

Therapeutical efficacy of Infliximab in rheumatoid arthritis

作　　者：喻灿球[1] 赵丽萍[1] 

机构地区：[1]中南大学湘雅二医院风湿免疫科,湖南长沙410011

出　　处：《中国现代医学杂志》2011年第5期682-683,共2页China Journal of Modern Medicine

摘　　要：目的观察英夫利西单抗治疗类风湿关节炎(RA)的临床疗效。方法选择该科门诊和住院RA患者18例,用英夫利西单抗治疗,观察用药前后临床症状和实验室指标。结果用药后6周患者关节肿胀、关节压痛数,ESR、CRP、RF及DAS28评分均明显改善(P<0.05)。结论英夫利西单抗是一种治疗类风湿关节炎安全、起效快、疗效显著的药物。【Objective】 To investigate the clinical efficacy of Infliximab on patients with rheumatoid arthritis（RA）.【Methods】 18 RA patients were treated with Infliximab and clinical and laboratory indices were recorded at the baseline and after Infliximab therapy.【Results】 6 weeks after Infliximab administration,the indices including swollen joints count（sjc）,tender joints count（tjc）,ESR,CRP,RF and DAS28 were significantly improved（P 0.05）.【Conclusion】 Infliximab can rapidly,efficaciously and safely relieve clinical signs and symptoms of RA.

关 键 词：类风湿关节炎 英夫利西单抗 

分 类 号：R593.22[医药卫生—内科学]